Agilent Technologies, Inc.

Agilent Technologies, Inc.

ANYSE / NASDAQHealthcareLarge cap

$170.38-$4.96 (-2.8%)

Last close · Data as of Nov 20, 2026

Market cap
$39.1B
P/E
30.0x
EV / EBITDA
22.1x
Revenue
$6.9B
Net margin
18.8%
ROCE
15.3%

+17.5% over the last year

Agilent Technologies, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.5%
3M
+9.0%
6M
+49.7%
1Y
+17.5%
5Y
+3.7%

52-week range

Day change -$4.96 (-2.8%) from $175 to $170 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in A, bought on each weekday since 2021.

News & filings

What Agilent Technologies filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity of 19.3% against a peer median of 23.0%.

Concerns (1)

  • EV / EBITDA of 22.1 against a peer median of 13.0.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems.

Read moreShow less

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Sector
Healthcare
Shares outstanding
283.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$39.1B
P/E
30.0x
P/B
5.8x
EV / EBITDA
22.1x
EV / Sales
5.8x
P/S
5.6x
52-week high
$181.48
52-week low
$110.24

Profitability

Operating margin
21.3%
Net margin
18.8%
EBITDA margin
26.4%
ROE
19.3%
ROCE
15.3%
ROA
10.2%
Asset turnover
0.55

Growth

Revenue
$6.9B
Revenue growth, 1Y
6.7%
Revenue CAGR, 3Y
0.5%
Net profit growth, 1Y
1.1%
Free cash flow
$1.2B

Solvency

Current ratio
1.96
Debt / Equity
0.50
Debt / Assets
0.26
CFO / Net profit
1.20
Cash / Market cap
4.6%

Where the revenue went

Of every $100 of FY2025 revenue, $19 was left as net income.

Agilent Technologies, Inc. income statement flow, FY2025
Agilent Technologies, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$3.3B
RevenueGross profit$3.6B
Gross profitResearch and development$455.0M
Gross profitSelling, general and administrative$1.7B
Gross profitOperating income$1.5B
Operating incomePretax income$1.4B
Operating incomeInterest and other expense$44.0M
Pretax incomeTax and other$132.0M
Pretax incomeNet income$1.3B

Revenue and net profit

Revenue grew 6.7% in FY2025; net profit is the dashed line.

Agilent Technologies, Inc. revenue and net profit by fiscal year
Agilent Technologies, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$6.8B$1.3B
FY2023$6.8B$1.2B
FY2024$6.5B$1.3B
FY2025$6.9B$1.3B

Cash flows

FY2025: $1.6B from operations, $1.2B free after investment (dashed).

Agilent Technologies, Inc. operating and free cash flow by fiscal year
Agilent Technologies, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$1.3B$1.0B
FY2023$1.8B$1.5B
FY2024$1.8B$1.4B
FY2025$1.6B$1.2B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$6.9B+6.7%1Y
EBITDA
$1.8B-2.1%1Y
Net profit
$1.3B+1.1%1Y
Cash from operations
$1.6B-11.0%1Y
Free cash flow
$1.2B-16.1%1Y
Revenue CAGR, 3Y
0.5%
Net profit CAGR, 3Y
1.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$6.9B$1.8B$1.3B$1.2B19.3%+6.7%+1.1%

Monthly returns

Month-by-month returns of A across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$12.7B
Liabilities$6.0B
Equity$6.7B
Paid-in capital$5.6B
Retained earnings$1.4B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; A highlighted.

P/E against peers

A trades at 30.0x earnings against a peer median of 30.0x.

Not shown (no positive earnings and no EV / Sales): Centene Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Agilent Technologies, Inc.Athis company$39.1B30.0x5.8x19.3%22.1x
IDEXX Laboratories, Inc.IDXX$44.5B42.0x27.7x66.0%30.1x
Humana Inc.HUM$42.0B35.4x2.4x6.7%—
Becton, Dickinson and CompanyBDX$41.2B24.6x1.6x6.6%12.1x
Alnylam Pharmaceuticals, Inc.ALNY$40.5B129.2x51.4x39.8%61.6x
Waters CorporationWAT$37.0B57.5x14.4x25.1%36.7x
Zoetis Inc.ZTS$33.3B12.5x10.0x80.2%9.9x
IQVIA Holdings Inc.IQV$31.2B22.9x4.8x20.9%13.0x
Centene CorporationCNC$31.0B-4.6x1.6x-33.4%-6.5x
Peer median—30.0x7.4x23.0%13.0x

Year-to-date ROI

A since 1 January, against earlier years.

Historical volatility

A's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Agilent Technologies, Inc. operating margin by fiscal year
Agilent Technologies, Inc. operating margin by fiscal year
DateOperating margin
FY202223.6%
FY202319.8%
FY202422.9%
FY202521.3%
LineFY2025
Cost of revenueCost Of Revenue$3.3B
Gross profitGross Profit$3.6B
Operating expensesOperating Expense$2.2B
Research and developmentResearch And Development$455.0M
Selling, general and administrativeSelling General And Administration$1.7B
Total expensesTotal Expenses$5.5B
Pretax incomePretax Income$1.4B

Learn while you research

Academy chapters picked for Agilent Technologies, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →